SenesTech Q1 revenue $415K record, up 78% YoY; Evolve drives >50% of sales

SenesTech, Inc.

2024-Q1 EPS reported -$0.36 revenue$415,000

Q1 2024 revenue $415,000, up 78% from $233,000 in Q1 2023; record quarterly revenue.
Net loss narrowed to $1.8M from $2.0M; adjusted EBITDA loss $1.7M vs $1.8M.
Evolve soft bait accounted for >50% of Q1 revenue; became biggest-selling product.
Launched Evolve Mouse in May 2024; extended distribution to Amazon, rep groups, 4,500 retail locations.
Cash at March 31, 2024 was $3.6M; New York City Council proposed deploying EPA-approved rat birth control.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SenesTech, Inc. reported first quarter ended March 31, 2024 results: revenue $415,000, net income $1.8 million.

Period: first quarter ended March 31, 2024
Revenue: $415,000
Net income: $1.8 million
Result: reported results

Exact text from the filing

EPA-registered Rat Birth Control ® products today announced financial results for the first quarter of 2024. Recent Highlights • Record quarterly revenues during Q1 2024 of $415,000, an increase of 78% compared to Q1 2023. • EvolveTM, formulated especially for the control of rat fertility and launched at the beginning of the year, has quickly become the

View on SEC.gov

Browse all earnings releases →

SenesTech, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-022205

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.